1.X-linked Myotubular Myopathy in a Family with Two Infant Siblings: A Case with MTM1 Mutation.
Ji Hyun JEON ; Ran NAMGUNG ; Min Soo PARK ; Kook In PARK ; Chul LEE ; Jin Sung LEE ; Se Hoon KIM
Yonsei Medical Journal 2011;52(3):547-550
X-linked myotubular myopathy (XLMTM) is a rare congenital muscle disorder, caused by mutations in the MTM1 gene. Affected male infants present severe hypotonia, and generalized muscle weakness, and the disorder is most often complicated by respiratory failure. Herein, we describe a family with 2 infants with XLMTM which was diagnosed by gene analysis and muscle biopsy. In both cases, histological findings of muscle showed severely hypoplastic muscle fibers with centrally placed nuclei. From the family gene analysis, the Arg486STOP mutation in the MTM1 gene was confirmed.
*Codon, Nonsense
;
Humans
;
Male
;
Muscle Hypotonia/genetics/pathology
;
Myopathies, Structural, Congenital/*genetics/pathology
;
Pedigree
;
Protein Tyrosine Phosphatases, Non-Receptor/*genetics
2.Research progress of several protein tyrosine phosphatases in diabetes.
Ming CHEN ; Jin-Peng SUN ; Jing LIU ; Xiao YU
Acta Physiologica Sinica 2010;62(2):179-189
Diabetes mellitus is caused by deficiency of insulin secretion from the pancreatic islet beta cells and/or insulin resistance in liver, muscle and adipocytes, resulting in glucose intolerance and hyperglycemia. Several protein tyrosine phosphatases, such as PTP1B (PTPN1), TCPTP (PTPN2), LYP (PTPN22), PTPIA-2, PTPMEG2 (PTPN9) or OSTPTP are involved in insulin signaling pathway, insulin secretion and autoreactive attack to pancreatic beta cells. Genetic mutation or overexpression of these phosphotases has been found to cause or increase the risk of diabetes mellitus. Some population with high risk for type 2 diabetes has overexpressed PTP1B, a prototypical tyrosine phosphatase which down-regulates insulin and leptin signal transduction. Animal PTP1B knockout model and PTP1B specific inhibitor cellular studies indicate PTP1B may serve as a therapeutic target for type 2 diabetes. TCPTP shares more than 70% sequence identity with PTP1B in their catalytic domain. TCPTP dephosphorylates tyrosine phosphorylated substrates overlapping with PTP1B but also has its own distinct dephosphorylation sites and functions. Recent research indicates TCPTP may have role in type 1 diabetes via dysregultaion of cytokine-mediated immune responses or pancreatic beta cell apoptosis. The tyrosine phosphatase LYP, which down-regulates LCK activity in T cell response, can become mutated as R620W which is highly correlated to type 1 diabetes. LYP R620W may be a gain of function mutation which suppresses TCR signaling. Patients bearing the R620W mutant have impaired T cell responses and increased populations of (CD45RO+CD45RA-) CD4+ T cells. A detailed elucidation of mechanism of R620W in type 1 diabetes and specific LYP inhibitor development will help characterize LYP R620W as a therapeutic target. A receptor tyrosine phosphatase, PTPIA-2/beta is a major autoantigen of type 1 diabetes. A diagnosis kit identifying PTPIA-2/beta autoantibodies is valuable in early detection and prevention of type 1 diabetes. In addition, other phosphatase like OSTPTP and PTPMEG2 are involved in type 2 diabetes via regulation of insulin production, beta cell growth or insulin signaling. Research into understanding the mechanism of these tyrosine phosphatases in diabetes, such as their precise functions in the regulation of insulin secretion, the insulin response and the immune response will strengthen our knowledge of diabetes pathophysiology which may result in new diagnostic and therapeutic strategies for diabetes.
Animals
;
Diabetes Mellitus
;
enzymology
;
Diabetes Mellitus, Type 1
;
enzymology
;
Diabetes Mellitus, Type 2
;
enzymology
;
Humans
;
Protein Tyrosine Phosphatase, Non-Receptor Type 1
;
genetics
;
metabolism
;
Protein Tyrosine Phosphatase, Non-Receptor Type 2
;
genetics
;
metabolism
;
Protein Tyrosine Phosphatase, Non-Receptor Type 22
;
genetics
;
metabolism
;
Protein Tyrosine Phosphatases, Non-Receptor
;
classification
;
genetics
;
metabolism
3.Expression and identification of type 1 diabetes associated autoantigen IA-2.
Xiujuan JIA ; Guo LI ; Zhan CHEN ; Guangwu XU ; Chao XIE ; Di ZHANG ; Wenzhong ZHOU ; Sheng ZHENG ; Xiaoyan XIE ; Jian YANG ; Jiping LI ; Min LUO
Chinese Medical Journal 2003;116(4):524-528
OBJECTIVESTo obtain prokaryotic expressed IA-2 recombinant protein and to identify its immunological activity.
METHODSThe complimentary DNA (cDNA) coding for the intracytoplasmic part of IA-2 (IA-2ic) was amplified from human fetal brain RNA, and was subcloned into the PinPoint Xa-1 T vector to construct recombinant expression plasmid, and was then expressed in E. coli JM109 cells as a fusion protein with a biotinylated peptide sequence at the aminoterminus. The biotinylated fusion protein was then purified by affinity chromatography and was subsequently dialyzed. Finally, its immunogenicity was evaluated by enzyme linked immunosorbent assay (ELISA).
RESULTSThe purified IA-2ic fusion protein resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as a single Coomassie brilliant blue stained band with a molecular weight of 59 kDa and its immunogenicity was confirmed by ELISA.
CONCLUSIONSE. coli expressed IA-2ic fusion protein has immunological activity. It can be used for detection of IA-2 autoantibodies (IA-2A) and for further studies on type 1 diabetes in future.
Animals ; Autoantigens ; biosynthesis ; DNA, Complementary ; analysis ; Diabetes Mellitus, Type 1 ; immunology ; Escherichia coli ; genetics ; Humans ; Membrane Proteins ; biosynthesis ; genetics ; isolation & purification ; Plasmids ; Protein Tyrosine Phosphatase, Non-Receptor Type 1 ; Protein Tyrosine Phosphatases ; biosynthesis ; genetics ; isolation & purification ; Rabbits ; Receptor-Like Protein Tyrosine Phosphatases, Class 8 ; Recombinant Fusion Proteins ; biosynthesis ; immunology ; isolation & purification
4.Mutation analysis of hematopoietic cell phosphatase gene in acute leukemia.
Jian-Min LUO ; Ze-Lin LIU ; Hong-Ling HAO ; Fu-Xu WANG ; Zuo-Ren DONG ; Ohno RYUZO
Journal of Experimental Hematology 2004;12(2):128-132
The hematopoietic cell phosphatase (HCP or SHP-1), the SH2 domain contain protein tyrosine phosphatase, is a crucial negative regulator in the process of hematopoietic cell development, proliferation and receptor-mediated mitogenic signaling pathways, and its mutation is responsible for the over-expansion and inappropriate activation of myelomonocytic population in motheaten mice. The aim of the study was to evaluate the role of the HCP gene in leukemogenesis. Bone marrow and/or peripheral blood from 32 acute myeloid leukemia (AML) patients, 9 acute lymphocytic leukemia (ALL) patients, 8 leukemia cell lines and 50 normal controls were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) based on single strand conformation polymorphism (SSCP) and sequencing. RT-PCR showed that all samples expressed HCP gene, only one missense mutation at codon 225 (AAC to AGC, Asn to Ser) within N-terminal SH2 domain was found in an ALL patient. In addition, four polymorphic base substitutions were detected in codon 69, 85, 86 and 266, respectively. In conclusion, mutation of HCP gene is an infrequent genetic aberration which may only play a role in pathogenesis of a small part of leukemia, however, its significance needs to be further clarified.
Acute Disease
;
Cell Line, Tumor
;
Humans
;
Intracellular Signaling Peptides and Proteins
;
Leukemia
;
enzymology
;
genetics
;
Mutation
;
Polymorphism, Single-Stranded Conformational
;
Protein Tyrosine Phosphatase, Non-Receptor Type 6
;
Protein Tyrosine Phosphatases
;
genetics
5.SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion.
Hui-ying HE ; Jie ZHENG ; Yan LI ; Wan-jie HENG ; Wei-gang FANG
Chinese Journal of Pathology 2005;34(5):288-292
OBJECTIVETo investigate the effects of protein tyrosine phosphatase-SHP2 and dual-specificity MAPK phosphatase-MKP5 on the activation of MAPKs and cell invasion induced by P2Y purinergic receptor in human prostate cancer cell lines with different metastatic potentials.
METHODSThe wide type (-wt) SHP2, mutant type (-cs) SHP2 and wide type (-wt) MKP5 cDNA expression vectors were constructed and stably transfected into 1E8 cells (highly metastatic) and/or 2B4 cells (non-metastatic). The tyrosine phosphorylation of SHP2 was examined by immunoprecipitation. The activation of ERK1/2 and p38 induced by P2Y receptor agonist ATP was analyzed by Western blot with phospho-specific antibodies against the dually phosphorylated, active forms of ERK1/2 and p38. The in-vitro invasive ability through Matrigel was measured by boyden-chamber assay.
RESULTSATP induced significant SHP2 phosphorylation, which was stronger and lasted longer in 1E8 than in 2B4. SHP2-wt enhanced the ERK1/2 activation induced by ATP in 2B4 cells, while SHP2-cs delayed and decreased this effect in 1E8 cells. Both SHP2-wt and SHP2-cs had no obvious influence on p38 activation. ATP stimulated cell invasion of both 1E8 and 2B4, while transfection of SHP2-wt into 2B4 cells further increased the invasive-stimulating ability of ATP (18.7% increase compared with ATP treatment alone). Transfection of SHP2-cs into 1E8 cells, however, antagonized the invasive-stimulating ability of ATP (40.9% decrease compared with ATP treated group). Up-regulation of MKP5-wt inhibited phosphorylation of p38 by ATP and reduced cell invasion stimulated by ATP (22.4% and 28.7% decrease compared with ATP treated group of 1E8 and 2B4, respectively).
CONCLUSIONSBoth SHP2 and MKP5 play some roles in P2Y receptor-mediated activation of MEK/ERK, p38 signaling pathways and prostate cancer invasion. SHP2 positively regulates ERK activation and prostate cancer invasion, whereas MKP5 inhibits the invasion by suppressing p38 activation.
Adenosine Triphosphate ; pharmacology ; Cell Line, Tumor ; DNA, Complementary ; genetics ; Dual-Specificity Phosphatases ; Genetic Vectors ; Humans ; Intracellular Signaling Peptides and Proteins ; genetics ; metabolism ; Male ; Mitogen-Activated Protein Kinase 1 ; metabolism ; Mitogen-Activated Protein Kinase 3 ; metabolism ; Mitogen-Activated Protein Kinase Phosphatases ; Neoplasm Invasiveness ; Phosphorylation ; Prostatic Neoplasms ; metabolism ; pathology ; Protein Tyrosine Phosphatase, Non-Receptor Type 11 ; Protein Tyrosine Phosphatases ; genetics ; metabolism ; Receptors, Purinergic P2 ; physiology ; Signal Transduction ; Transfection ; p38 Mitogen-Activated Protein Kinases ; metabolism
6.Construction of MicroRNA-Target Interaction Networks Based on MicroRNA Expression Profiles of HRV16-infected H1-HeLa Cells.
Qin Qin SONG ; Yan Hai WANG ; Xin Ling WANG ; Bing Tian SHI ; Rui Fang WANG ; Juan SONG ; Wen Jun WANG ; Dong XIA ; Zhi Qiang XIA ; Qiang WEI ; Jun HAN
Biomedical and Environmental Sciences 2022;35(9):854-860
In the present study we investigated the changes in miRNA levels inhuman rhinovirus 16 (HRV16)-infected cells. A small RNA deep sequencing experiment was performed through next-generation sequencing. In total, 53 differentially expressed miRNAs were confirmed by RT-qPCR, including 37 known miRNAs and 16 novel miRNAs. Interaction networks between differentially expressed miRNAs and their targets were established by mirDIP and Navigator. The prediction results showed that QKI, NFAT5, BNC2, CELF2, LCOR, MBNL2, MTMR3, NFIB, PPARGC1A, RSBN1, TRPS1, WDR26, and ZNF148, which are associated with cellular differentiation and transcriptional regulation, were recognized by 12, 11, or 9 miRNAs. Many correlations were observed between transcriptional or post-transcriptional regulation of an miRNA and the expression levels of its target genes in HRV16-infected H1-HeLa cells.
CELF Proteins/metabolism*
;
DNA-Binding Proteins/genetics*
;
Gene Expression Profiling
;
Gene Expression Regulation
;
HeLa Cells
;
High-Throughput Nucleotide Sequencing
;
Humans
;
MicroRNAs/metabolism*
;
Nerve Tissue Proteins/genetics*
;
Protein Tyrosine Phosphatases, Non-Receptor
;
Repressor Proteins/metabolism*
;
Sequence Analysis, RNA
;
Transcription Factors/metabolism*
7.Expression of Ref-1 and FAP-1 mRNA in hypoxic-ischemic injury in neonatal rat.
Chun DENG ; Chun-bao GUO ; Jia-lin YU ; Shi-xiao WU ; Yi TAN
Chinese Journal of Pediatrics 2003;41(4):297-299
Animals
;
Animals, Newborn
;
Brain
;
blood supply
;
metabolism
;
pathology
;
Carrier Proteins
;
genetics
;
DNA-(Apurinic or Apyrimidinic Site) Lyase
;
genetics
;
Gene Expression
;
Hypoxia-Ischemia, Brain
;
genetics
;
pathology
;
In Situ Hybridization
;
Protein Tyrosine Phosphatase, Non-Receptor Type 13
;
Protein Tyrosine Phosphatases
;
genetics
;
RNA, Messenger
;
genetics
;
metabolism
;
Rats
;
Rats, Wistar